Jaguar Health, Inc. (Jaguar), known for its Jaguar Animal Health division dedicated to veterinary care, has announced its pursuit of a strategic collaborator to finance and facilitate the progression and market introduction of NP300. This prescription drug, aimed at tackling general, non-infectious diarrhoea in dogs, offers the potential for exclusive commercial rights within the United States for the partner involved.
NP300 introduces a pioneering antisecretory treatment similar to Canalevia-CA1 (consisting of crofelemer delayed-release tablets), Jaguar’s previously conditionally approved remedy for managing chemotherapy-induced diarrhoea (CID) in canines. With proven safety in dogs and an eco-friendly extraction from the Croton lechleri tree—the very source for crofelemer—the drug holds promising potential.
“We anticipate extensively evaluating NP300’s application for standard non-infectious diarrhoeal symptoms in dogs while actively searching for a partner to oversee both its development and market distribution,” stated David Sesin, PhD, the Chief Manufacturing Officer of Jaguar. “Our experiences with crofelemer’s acceptance for treating CID in dogs highlight a clear existing gap demanding a reliable solution for general non-infectious diarrhoea in dogs. With approximately six million acute and chronic diarrhoeal cases reported by US veterinarians annually, we recognize the immediate need.
Diarrhoea remains a prevalent cause for both standard and emergency veterinary consultations for dogs, yet no FDA-approved remedy currently exists. According to the American Veterinary Medical Association, 2024 estimates put the US dog population at about 89.7 million, with nearly half the households (45.5%) owning a dog. Rapid dehydration from diarrhoea can be a dire challenge, exacerbated in urban areas where owners struggle with limited access to convenient outdoor facilities, causing additional family distress.
Jaguar Health, Inc. operates as a commercial-stage pharmaceutical entity dedicated to pioneering proprietary prescription drugs sustainably sourced from rainforest plant species. Their mission encompasses addressing gastrointestinal ailments characterized by symptoms such as relentless diarrhoea, urgency, bowel control loss, and painful cramps, thereby improving animal and human health.